Previous studies have demonstrated that expanding LMP1/EBNA1-specific CTLs by coculturing with irradiated autologous PBMCs infected with an adenoviral vector encoding EBNA1 and multiple CTL epitopes from LMP1 and LMP2 (AdE1-LMPpoly), followed by reinfusion into EBV-positive recurrent and metastatic NPC patients, effectively controlled tumor progression with a median OS of 17.2 months [134]. This evidence concerns the gene PDLIM7 and neoplasm.